Opinion

Video

The Role of Genomic Classifiers in Guiding Therapy for Localized High-Risk Prostate Cancer

A panelist discusses how genomic classifiers play a crucial role in determining whether treatment intensification with agents like abiraterone is beneficial for patients with high-risk localized prostate cancer.

High-Risk Localized Prostate Cancer Case Presentation

This segment introduces a patient aged 62 years with high-risk localized prostate cancer, demonstrating the expanding role of abiraterone beyond metastatic disease treatment. The patient presented with an elevated prostate-specific antigen (PSA) of 25, leading to prostate biopsy revealing Gleason 4+5=9 cancer in 4 of 12 cores. Staging with PSA PET scan showed questionable right-sided pelvic lymph node involvement but no definitive distant metastases, representing a challenging clinical scenario requiring multidisciplinary treatment planning.

The patient’s medical history includes well-controlled hypertension and hyperlipidemia without significant cardiovascular disease or diabetes. Family history reveals paternal prostate cancer, and genomic classifier testing demonstrated high-risk signature, supporting treatment intensification. Physical examination showed good performance status (ECOG 0) with a firm, irregular prostate consistent with high-grade localized disease, making him an appropriate candidate for curative-intent therapy.

After multidisciplinary discussion considering surgery, radiation, and systemic therapy options, the patient elected definitive radiation therapy combined with androgen deprivation therapy. Given high-risk clinical and genomic features, treatment intensification with abiraterone was recommended. The case demonstrates successful PSA response from 25 to 2.1 at 1 month but highlights ongoing challenges with traditional abiraterone tolerability, leading to consideration of alternative formulations.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
2 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.